Back to today’s briefing

Story perspectives

AstraZeneca's Tezspire Revolutionizes Asthma Treatment Amid Access Issues

2/20/2025

45 5

Summary

Story summary

AstraZeneca's Tezspire (tezepelumab) revolutionizes severe asthma treatment by directly targeting thymic stromal lymphopoietin (TSLP), eliminating the need for biomarker testing. However, in Korea, reimbursement challenges hinder access, leaving only 10-20% of eligible patients able to afford this breakthrough. Experts urge for earlier use of biologics to enhance patient outcomes and quality of life.

1 of 1

Story summary

AstraZeneca's Tezspire (tezepelumab) revolutionizes severe asthma treatment by directly targeting thymic stromal lymphopoietin (TSLP), eliminating the need for biomarker testing. However, in Korea, reimbursement challenges hinder access, leaving only 10-20% of eligible patients able to afford this breakthrough. Experts urge for earlier use of biologics to enhance patient outcomes and quality of life.